Compare Las Vegas Sands Corp. (LVS) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Las Vegas Sands Corp. trades at $36.36 (market cap $23.38B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.62 (market cap $25.27B). The key difference: Las Vegas Sands Corp. and Royalty Pharma plc Class A Ordinary Shares are close in size by market cap, and Las Vegas Sands Corp. pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| LVS | RPRX | |
|---|---|---|
Market Cap | $23.38B | $25.27B |
Volume | 6,994,661 | 3,671,183 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $63.96 |
52-Week Low | $35.81 | $35.44 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $35.27B | $32.50B |
Dividend Yield | 3.32% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $35.81, down 1.38% today, with a bearish technical signal despite bullish oscillators. The company shows strong fundamentals with 2025 revenue of $13.02B and net income of $1.63B, supported by consistent earnings beats in recent quarters. Analyst consensus remains strongly bullish with 59% buy ratings and a $59.78 price target, representing 67% upside potential from current levels.
LVS presents compelling value with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). Key risks include high debt levels (debt-to-asset ratio 73.15%) and sensitivity to Macao gaming regulations. The stock's current discount to analyst targets offers significant upside if operational momentum continues.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
